Products
Pre-made Bemarituzumab benchmark antibody ( Whole mAb, anti-FGFR2 therapeutic antibody, Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-057
Pre-Made Bemarituzumab biosimilar, Whole mAb, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bemarituzumab (Amgen) is an investigational targeted antibody designed to block fibroblast growth factors from binding and activating FGFR2b. ... chemotherapy alone as first-line therapy for patients with FGFR2b-positive, non-HER2-positive advanced gastric or gastroesophageal cancers.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-057-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Bemarituzumab biosimilar, Whole mAb, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody |
| INN Name | Bemarituzumab |
| Target | FGFR2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Five Prime Therapeutics;ZAI Lab |
| Conditions Approved | na |
| Conditions Active | Gastric cancer |
| Conditions Discontinued | Oesophageal cancer;Solid tumours |
| Development Tech | POTELLIGENT Technology |
